July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Visual and anatomical outcomes following cataract surgery in patients with retinal vein occlusions treated with intravitreal anti-vascular endothelial growth factor injections
Author Affiliations & Notes
  • Matthew Starr
    Mayo Clinic, Rochester, Minnesota, United States
  • Michael Mahr
    Mayo Clinic, Rochester, Minnesota, United States
  • Andrew Barkmeier
    Mayo Clinic, Rochester, Minnesota, United States
  • Raymond Iezzi
    Mayo Clinic, Rochester, Minnesota, United States
  • Sophie Bakri
    Mayo Clinic, Rochester, Minnesota, United States
  • Footnotes
    Commercial Relationships   Matthew Starr, None; Michael Mahr, None; Andrew Barkmeier, None; Raymond Iezzi, None; Sophie Bakri, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2561. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Matthew Starr, Michael Mahr, Andrew Barkmeier, Raymond Iezzi, Sophie Bakri; Visual and anatomical outcomes following cataract surgery in patients with retinal vein occlusions treated with intravitreal anti-vascular endothelial growth factor injections. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2561.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to investigate the outcomes of cataract surgery in patients with retinal vein occlusions (RVO) who were actively managed with intravitreal anti-vascular endothelial growth factor (VEGF) before and after cataract surgery.

Methods : We examined all patients who underwent cataract surgery and were receiving intravitreal anti-VEGF injections from January 1st, 2012 through December 31st, 2017. There were 20 eyes that underwent cataract surgery and received at least one intravitreal anti-VEGF injection for a diagnosis of RVO within 6 months prior to surgery. Data collected included the development of subretinal or intraretinal macular fluid in the 6 months following surgery, timing of injections, number of injections, best corrected visual acuity (BCVA), and central subfield thickness (CST).

Results : There was a significant improvement between pre- and post-operative BCVA when comparing all eyes (p values <0.0001) and no significant difference in CST before and after surgery (p >0.05). Twelve eyes (60%) developed new or worsening macular fluid post-operatively on optical coherence tomography. These eyes demonstrated a significant improvement in visual acuity (p = 0.019 at 1 month and p = 0.018 at 6 months) with no significant worsening of their retinal thickness (p values >0.05). Eleven eyes (55%) had macular fluid pre-operatively. These eyes saw a significant improvement in visual acuity (p = 0.02 at 1 month and p = 0.04 at 6 months) with no worsening of the CST.

Conclusions : In a real world setting, patients with cataracts who are actively managed for RVO with anti-VEGF agents may undergo cataract surgery and see an improvement in their visual acuity. More than half of eyes developed worsening macular fluid which required persistent therapy, but this fluid did not appear to affect 6 month visual outcomes. Eyes did not have to be fluid-free pre-operatively to see a significant improvement in visual acuity.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×